Abstract:Background: Studies have shown that ERBB3 mutations are associated with poor clinical prognosis by increasing the rate of metastasis and recurrence in many cancers. ERBB3 targeted therapeutics can be effective against ERBB3 mutant-driven tumors. ERBB signal pathway plays a very important role in the initiation and progression of gastric cancer, however the ERBB2 expression and mutation rate is relative low especially in gastric SRCC. Thus, ERBB3 might be a promising target for the treatment in SRCC patients. The aim of this study is to speculate the prognostic and targeted therapy value in gastric SRCC by evaluating the mutation rate and type of ERBB3. Methods: 92 patients with histological diagnosis of advanced gastric SRCC were retrospectively selected for this study. ERBB3 mutation was evaluated by next generation sequencing from formalin-fixed paraffin-embedded (FFPE) samples. ERBB2 expression was tested by immunohistochemistry. Correlations between ERBB2/3 status and clinical pathologic characteristics and overall survival (OS) were performed. Results: All of the 92 patients were diagnosed as local advanced or metastatic gastric SRCC (92.4% were stage III, 7.6% were stage IV). All the patients received 5-FU-based first-line chemotherapy. 14 out of all 92 patients were ERBB3 mutated SRCC, 12 of all the 14 mutations were in the extracellular domain, 2 were in the transmembrane region. There was no correlation between ERBB3 mutation and serosa invasion (P = 0.389) or lymph node metastasis (P = 1.000). The median OS was 20.5 months (95% CI = 10.05to 30.95 months) for patients with ERBB3 mutation, and 19.0 months (95% CI = 15.54 to 22.46 months) for patients without ERBB3 mutation (P = 0.567). There was no difference in OS according to HER2 positive or negative in ERBB3 mutated patients (14.8 months vs 20.5 month, P = 0.374). Conclusions: Our study demonstrated 15.2% of gastric SRCC patients harboring ERBB3 mutation, providing a potential subgroup of gastric SRCC for targeted treatment on ERBB pathway. No difference of OS was observed, probably due to the relative small sample size and low ERBB2 positive rate in SRCC patients. Further investigation on ERBB3 is warranted to clarify mechanisms of ERBB pathway in gastric SRCC. Legal entity responsible for the study: The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, China Funding: None Disclosure: All authors have declared no conflicts of interest.

Evaluation Of Driver Mutations Involving In Ras-Raf/Pi3k-Mtor Pathway In Gastric Signet Ring Cell Carcinoma.

P-054 Evaluation of Driver Mutations Involving in RAS-RAF/PI3K-mToR Pathway in Gastric Signet Ring Cell Carcinoma

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due To Modulation Of Proliferative And Invasive Ability Of Gastric Cancer

Targeted-sequencing and Comprehensive Molecular Profiling of Gastric Signet Ring Cell Carcinoma

Abstract 3177: KRAS Gene Status in Gastric Signet-Ring Cell Carcinoma Patients and Act As Biomarker of MEK Inhibitor

Erbb Pathway Alterations In Advanced Gastric Signet-Ring Cell Carcinoma (Srcc) And The Implications For Targeted Therapy.

ERBB3 Mutations in Advanced Gastric Signet-Ring Cell Carcinoma (SRCC) and the Implications for Targeted Therapy

Driver Gene Alterations in Malignant Progression of Gastric Cancer

Mutational analysis of driver genes with tumor suppressive and oncogenic roles in gastric cancer

Establishment And Characterization Of Gcsr1, A Multi-Drug Resistant Signet Ring Cell Gastric Cancer Cell Line

Immunosuppressive tumor microenvironment in gastric signet-ring cell carcinoma

Identification of key genes and pathways in gastric signet ring cell carcinoma based on transcriptome analysis

The mechanism of RGS5 regulating gastric cancer mismatch repair protein

KRAS Mutation and Protein Levels in Gastric Cancer Patients and Response to MEK Inhibitors

Integrated analysis identities Rho GTPases related molecular map in patients with gastric carcinoma

Prognostic prediction and treatment options for gastric signet ring cell carcinoma: a SEER database analysis

Clinicopathological Characteristics and Prognosis of Signet Ring Gastric Cancer: A Population-Based Study

Gene mutation profiling and clinical significances in patients with renal cell carcinoma

The Pathway Regulating Rhoa Activity To Predict The Survival Of Gastric Cancers.

Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.